Trump administration brokers obesity drug pricing pact with Novo and Lilly; FDA approves daratumumab for earlier-line myeloma; geopolitical tensions ease for Illumina while BD navigates
Healthcare markets exploded with deal-making activity as November opened with a bang. Novartis dropped $12 billion to acquire Avidity Biosciences, Novo Nordisk and Pfizer escalated
The healthcare sector delivered a remarkable week of innovation, deal-making, and regulatory transformation. From the FDA’s groundbreaking National Priority Review program to over $6.4 billion
Markets experienced significant turbulence this week as banking sector concerns collided with healthcare earnings, policy developments, and robust deal-making activity. Here’s everything you need to
Explore the latest biotech innovations from October 6-13, 2025: AstraZeneca’s oncology trials, FDA approvals for IPF and CSCC, allogeneic CAR-NK cells, and trends in direct-to-consumer
The final week of September brought seismic shifts across the pharmaceutical and biotechnology sectors, with an $8 billion oncology acquisition, leadership changes at Big Pharma
The shift from intravenous to subcutaneous drug administration is accelerating across oncology and immunology, fundamentally changing how patients receive treatment and how healthcare systems manage
Merck just scored FDA approval for Keytruda QLEX, a subcutaneous formulation of pembrolizumab that can be administered in 1-2 minutes instead of a 30-minute IV
The FDA just delivered hope to families dealing with one of childhood’s most challenging rare diseases. In a groundbreaking decision, the agency has expanded access
4,000-patient real-world study validates optimal ADC sequencing, driving strong investor confidence in precision oncology platform Caris Life Sciences shares surged following publication of breakthrough results
